Rezolute Inc (RZLT)
Rezolute, Inc. is a NASDAQ-listed common stock of a biotechnology company focused on late-stage rare disease programs. The company is working to improve outcomes for people in the United States who experience hypoglycemia related to hyperinsulinism. Its lead clinical candidate is ersodetug, a human monoclonal antibody administered intravenously and being evaluated in Phase 3 studies for congenital hyperinsulinism, a rare pediatric genetic disorder, as well as for hypoglycemia. Rezolute is also conducting clinical trials of ersodetug in tumor hyperinsulinism. The company was founded in 2010, adopted the Rezolute name in December 2017, and is headquartered in Redwood City, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RZLT
|
$3.73
|
-22.9% Downside
|
Overvalued
|
$7.67
|
58.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 10, 2026
|
-6.2x
|
4.3x
|
—
|
464.9 M
|
386.5 M
|
0.2%
|
68.5%
|
26.0
|
—
|
90.2%
|
